Nationwide epidemiology of HPV E6/E7 mRNA in China
Genotype distribution in 11,118 women
Bibliographic Data
| ID | 22071037 |
|---|---|
| Authors | Shengyang Xu (0000-0002-5363-1522, Dian Diagnostics (China)), Yan Li (0000-0001-6650-7726, Tianjin First Center Hospital), Xunfei Yi (Guangzhou Biotron Biotechnology Co., Ltd), Zhanli Yan (Dian Diagnostics (China)), Tiantian Zeng (Dian Diagnostics (China)), Ning Meng (Guangzhou Biotron Biotechnology Co., Ltd), Jingna Sun (First Affiliated Hospital of Hebei Medical University) |
| Year | 2026 |
| Volume | 14 |
| Pages | 1797051-1797051 |
| Publication date | 2026-04-24 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2026.1797051 |
| PMID | 42110258 |
| OpenAlex | W7155531287 |
| Language | EN |
| References cited | 24 |
Background: Persistent infection with carcinogenic human papillomavirus (HPV) is the necessary cause of cervical cancer. However, the distribution of transcriptionally active high-risk HPV genotypes across age groups and geographic regions in China remains insufficiently characterized. We aimed to define the nationwide epidemiologic profile of HPV E6/E7 mRNA positivity in China and to evaluate age-, region-, and proxy-defined source-population heterogeneity. Methods: In this retrospective cross-sectional study, 11,118 female cervical specimens retrieved for HPV E6/E7 mRNA testing between August 14, 2024 and October 23, 2025 were analyzed from seven geographic regions of China. Fourteen high-risk HPV genotypes were detected using the Biotron HPV E6/E7 mRNA Genotyping Assay. Descriptive, co-detection, and multivariable logistic regression analyses with institution-level cluster-robust standard errors were performed. Results: Overall high-risk HPV E6/E7 mRNA positivity was 16.32% (1,815/11,118). HPV52, HPV58, and HPV16 were the dominant genotypes, followed by HPV18 and HPV51. Overall positivity varied significantly across age groups, regions, institution-level proxy categories, and department-based clinical-context proxy categories. Central China had the highest overall positivity rate, whereas East China had the lowest. Significant age-related heterogeneity was observed for several major genotypes, especially HPV52, HPV58, and HPV16. Multi-type positivity accounted for 11.8% of positive samples, with HPV52 and HPV58 forming the most prominent co-detection pattern. In multivariable analyses, older age and several non-East regions were associated with higher odds of overall positivity, whereas the opportunistic screening proxy group showed markedly lower odds of positivity than the gynecology-related clinical attendance proxy group. Conclusion: Transcriptionally active high-risk HPV infection in China is characterized by dominance of HPV52, HPV58, and HPV16 and by marked heterogeneity across age, geography, and proxy-defined testing contexts. These findings may support more refined HPV surveillance and risk-adapted prevention strategies
Cervical cancer · Genotype · Genotyping · HPV infection · Logistic regression · Odds · Odds ratio · Cervical Cancer and HPV Research · Head and Neck Cancer Studies · Reproductive tract infections research · Epidemiology
HPV Prevalence and Genotype Distribution Among Women From Hengyang District of Hunan Province, China
Cervical HPV infection in Yueyang, China
HPV prevalence and genotype distribution in 2,306 patients with cervical squamous cell carcinoma in central and eastern China
Epidemiology and genotypes analysis of human papillomavirus infection in Huizhou, China
Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology
| Citation velocity | historical |
|---|---|
| Highly cited | No |